Tetyana Vasylyeva
Pediatric Nephrology · Amarillo, TXNPI 1255542023
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $338 of the $398 with a category attached, or 85.0%. 7 manufacturers reported payments, led by AstraZeneca at 47.6% of the total. 2025 is the largest year on record at $222, more than ten times the $20 reported in 2020.
Across 9 payments — averaging $44.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$189
- Rhythm Pharmaceuticals, Inc.$60
- Apellis Pharmaceuticals, Inc.$51
- Vifor Pharma, Inc.$46
- Tolmar Pharmaceuticals, Inc.$20
- Ultragenyx Pharmaceutical Inc.$16
- plus $16 from 1 others
Across 28 payments — averaging $10,257 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$252K
- Boehringer Ingelheim$19K
- Travere Therapeutics, Inc.$8K
- Mallinckrodt Enterprises LLC$4K
- Boehringer Ingelheim International GmbH$2K
- Vifor Pharma, Inc.$1K
- plus $178 from 1 others
What the payments were for
- Food & beverage$33885%
- Education$6015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $189 |
| Rhythm Pharmaceuticals, Inc. | 1 | $60 |
| Apellis Pharmaceuticals, Inc. | 2 | $51 |
| Vifor Pharma, Inc. | 1 | $46 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$398 in reported general payments places this provider in the 55th percentile of 61 pediatric nephrology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 11 | $850 |
| Tacrolimus | 13 | $667 |
| Amlodipine Besylate | 22 | $13 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Amarillo
- Amy BeckerCorpus Christi$77K
- Mini MichaelHouston$25K
- Rita SwinfordHouston$25K
- Ewa ElenbergHouston$16K
- Robert GillespieFort Worth$11K
- Melissa CadnapaphornchaiSan Antonio$10K
- Samhar Al AkashCorpus Christi$9K
- Raymond QuigleyDallas$7K
- Albert QuanDallas$6K
- Mouin SeikalyDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.